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For the majority of patients with pancreas cancer,
the highmetastatic proclivity is life limiting. Some pa-
tients, however, present with and succumb to locally
destructive disease. A molecular understanding of
these distinct disease manifestations can critically
inform patient management. Using genetically engi-
neered mouse models, we show that heterozygous
mutation of Dpc4/Smad4 attenuates the metastatic
potential of KrasG12D/+;Trp53R172H/+ pancreatic
ductal adenocarcinomas while increasing their
proliferation. Subsequent loss of heterozygosity of
Dpc4 restores metastatic competency while further
unleashing proliferation, creating a highly lethal com-
bination. Expression levels of Runx3 respond to and
combine with Dpc4 status to coordinately regulate
the balance betweencancer cell division anddissem-
ination. Thus, Runx3 serves as both a tumor suppres-
sor and promoter in slowing proliferation while
orchestrating a metastatic program to stimulate cell
migration, invasion, and secretion of proteins that
favor distant colonization. These findings suggest
a model to anticipate likely disease behaviors in
patients and tailor treatment strategies accordingly.INTRODUCTION
Patients with carcinomas die primarily of metastatic disease.
This is especially true of pancreatic ductal adenocarcinoma
(PDA), which is notorious for its early and extreme penchant
for dissemination. A minority of patients instead presents
with and succumbs to locally advanced disease, although the
reasons for these distinct presentations remain unknown. PDA
has either overtly metastasized or advanced locally beyond the
boundaries of surgical resection in most patients at the time of
diagnosis; subsequent median survival is approximately 4.5
and 10.6 months, respectively (Hidalgo, 2010). For the fortunate
few for whom surgical resection is possible, median survival
increases to 2 years but is not durable: survival at 5 years isonly 20% and declines to less than 2% at 10 years (Allison
et al., 1998). The majority of these post-operative patients also
eventually die of metastatic disease suggesting that clinical
stage I tumors are, in fact, already micrometastatic stage IV.
In a uniformly lethal disease, prognosis per se may be less
informative than the ability to predict disease behaviors and
likely proximal cause of death to help inform rational treatment
decisions. Indeed, neoadjuvant strategies for early-stage PDA
were introduced because many patients ultimately die from
distant relapse after surgery; addressing this reality with a course
of chemotherapy prior to resection can prolong survival but
runs the attendant risk of local tumor growth beyond surgical
boundaries and therefore a lost chance for cure. Thus, knowing
when to operate or irradiate and when to treat systemically
remains unclear.
PDA begins most commonly in precursor lesions termed
pancreatic intraepithelial neoplasms (PanIN) that arise in terminal
ductules (Hruban et al., 2001). Activating KRASmutations occur
early in preinvasive disease and are almost uniformly present
(>90%) in invasive PDA. Mutations in CDKN2A/INK4A are simi-
larly abundant in invasive disease (>95%) and point mutations
in TP53 are also common (>75%). Loss of DPC4/SMAD4
expression, the last of the principal genetic events associated
with PDA, occurs late in PanIN-to-PDA progression and is
seen in approximately 50% of invasive cancers (Iacobuzio-
Donahue et al., 2000).
Engineering these cardinal mutations into themurine pancreas
has yielded important insights into mechanisms underlying
initiation, progression, and maintenance of PDA, as well as the
non-cell autonomous contributors to disease biology (Pe´rez-
Mancera et al., 2012; Stromnes et al., 2014). Collectively, these
studies suggest that distinct combinations of tumor suppressor
gene mutations can alter the pace, phenotype, and prognosis
of the resultant invasive disease. For example, concomitant
mutations in p16/p19 (Aguirre et al., 2003) or Trp53 (Hingorani
et al., 2005) hasten progression initiated by oncogenic Kras
(Hingorani et al., 2003), albeit with distinct characteristics. In
the case of biallelic p16/p19 loss, the primary tumor progresses
rapidly, leading to early death and minimal metastatic disease.
KrasLSL-G12D/+;Trp53LSL-R172H/+;Cre (KPC) animals instead suc-
cumb from a combination of both primary and metastatic
tumor burdens that closely mimics the common presentation in
humans. In contrast, heterozygous deletion of Dpc4/Smad4Cell 161, 1345–1360, June 4, 2015 ª2015 Elsevier Inc. 1345
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Figure 1. Molecular Characterization of Tumor Progression in KPDC Mice
(A) Kaplan-Meier survival of KPDC animals (167 days) was significantly less than control animals (769 days, p < 0.001), KrasLSL-G12D/+;
Dpc4flox/+;p48Cre/+ (KDC) mice (479 days, p < 0.001), and KPC mice (209 days, p < 0.05) (log rank test for each pairwise combination).
(B and C) Gross pathology of KPDC pancreata at necropsy. Dashed lines, tumor.
(D) Representative KPDC tumor.
(E) Representative KPC tumor.
(F) Pancreas histology in young KPDC animal (age = 109 days). Arrow, PanIN-1A.
(G) Pancreas histology in older KPDC animal (age = 165 days). Arrow, PanIN-3.
(H) Moderately well-differentiated KPDC PDA.
(I) Poorly differentiated KPDC PDA.
(J) CK-19 immunoreactivity highlights KPDC ductal epithelium. Arrows, PanIN-1A; arrowhead, normal duct.
(K) Alcian blue histochemistry (arrow) reveals mucin content in preinvasive KPDC lesion.
(legend continued on next page)
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in the context of oncogenic KrasG12D expression generates
macroscopic cystic precursors known as mucinous cystic
neoplasms (MCN) (Izeradjene et al., 2007). Subsequent
progression to invasive PDA occurs through additional sponta-
neous events including loss of heterozygosity (LOH) of Dpc4,
but the disease manifests an attenuated metastatic potential.
Invasive PDA that arise from MCN in patients also invariably
lose DPC4 expression (Iacobuzio-Donahue et al., 2000) and
have a better prognosis than cancers following the more
common PanIN-to-PDA route (Crippa et al., 2008). Thus,
perhaps unexpectedly, decreased transforming growth factor
b (TGF-b) signaling in certain contexts can give rise to less
aggressive PDA.
Continuing these investigations into the pathophysiology of
distinct genetic and histologic subtypes of PDA, we engineered
targeted heterozygous mutation of Dpc4 with concomitant
point mutant Trp53R172H and oncogenic KrasG12D in the murine
pancreas and defined the resulting disease. We describe a
biphasic dependency of Runx3 levels on Dpc4 gene dosage
that helps to predict and explain three potential disease presen-
tations in patients. The predicted behaviors can, in turn, inform
the rational application and timing of local versus systemic
therapies to maximize survival.
RESULTS
Concomitant Trp53 Mutation Restores PanIN-to-PDA
Progression in the Context of KrasG12D Expression
and Dpc4 Deletion
Conditional endogenous expression and deletion of critical
genes (Figure S1A) were targeted to the developing murine
pancreas using strategies described previously (Hingorani
et al., 2003, 2005; Izeradjene et al., 2007). We first established
that animals with targeted pancreatic expression of point
mutant p53 and concomitant heterozygous deletion of Dpc4/
Smad4, in the absence of oncogenic KrasG12D, developed and
aged normally with unperturbed pancreatic parenchymal archi-
tecture and intact exocrine and endocrine synthetic functions
(Figure S1B).
To investigate the effects of concomitant p53 and Dpc4muta-
tion on neoplasms initiated by oncogenic Kras, KrasLSL-G12D/+;
Trp53LSL-R172H/+;Dpc4flox/+;p48Cre/+ (KPDC) quadruple mutant
mice were generated and aged until symptomatic. Concomitant
heterozygous deletion of Dpc4 shortened survival compared
with KrasLSL-G12D/+;Trp53LSL-R172H/+;p48Cre/+ (KPC) littermates
(Figure 1A). KPDC animals developed solid, multinodular tumors
similar to those of KPC mice (Figures 1B and 1C), albeit much
larger (Figures 1D and 1E). Histologic progression in KPDC
mice followed the classical PanIN-to-PDA and not MCN-to-
PDA sequence. Low-grade PanIN were seen in young animals
and subsequently progressed to higher grade and then to inva-
sive PDA (Figures 1F–1I). CK-19 expression (Figure 1J)(L) Metastatic potential (% with metastases) in KPDC (+/) and KPC (+/+) animal
Dpc4, respectively.
(M) Immunoblots of representative KPDC and KPC primary PDA cell lysates from
d, duodenum; ac, acinar cells. Scale bars, 50 mm. See also Table S1 and Figureconfirmed the ductal epithelial nature of these neoplasms, and
Alcian blue revealed their abundant cytoplasmic mucin (Fig-
ure 1K). The histologic morphology was predominantly glandular
(Table S1) and other less common histologies seen in human
PDA, including anaplastic and sarcomatoid, were similarly rare
in KPDC tumors.
Haploinsufficiency of Dpc4 Attenuates the Metastatic
Drive of KrasG12D and Trp53R172H
Belying their earlier demise, KPDC animals manifested an unex-
pected and significant decrease in metastatic disease. Their
KPC littermates developed widely disseminated disease as
described previously (Hingorani et al., 2005), with a heavy
macroscopic tumor burden, principally to the liver (53%) and
lungs (47%) (Figure 1L). In contrast, only 21% of KPDC litter-
mates developed macroscopically evident metastases, which
were largely confined to the liver (Figure 1L; Table S1). Moreover,
as most metastases in KPDC mice were microscopic, they did
not contribute substantively to overall tumor burden. Thus, the
evolution of pancreas cancer in KPDC mice is shifted toward a
higher primary tumor burden and less metastatic disease.
Genetic Progression of KPDC PDA
To investigate the basis for the distinct in vivo biological behavior
of KPDC PDA, we purified primary ductal carcinoma cells as
previously described (Hingorani et al., 2005; Schreiber et al.,
2004). We first confirmed that the purified PDA cells had
recombined and activated the conditional KrasLSL-G12D and
Trp53LSL-R172H alleles, and likewise deleted the Dpc4 allele
(Figures S1C–S1E). Disease progression was invariably accom-
panied by spontaneous LOH of Trp53 (Figure S1D), as typically
occurs in murine (Hingorani et al., 2005) and human (Scarpa
et al., 1993) PDAwith point mutations in one TP53 allele. Invasive
KPDC PDA cells typically did not undergo LOH of Dpc4 but
instead frequently retained the remaining wild-type (WT) allele
(Figure S1E) and persistent protein expression (Figure 1M), un-
like the spontaneous loss or epigenetic silencing of the second
allele that occurs in KDC mice during disease progression (Izer-
adjene et al., 2007). Detectable levels of Trp53 were observed
consistent with point mutant expression and LOH. Cdkn2a/
Ink4a (p16) expression was frequently lost, although that of
the contiguous p19 allele was retained, suggesting specific
promoter methylation rather than genomic deletion as the mech-
anism of silencing (Izeradjene et al., 2007). The loss of p16 is
notable as prior studies of both KPC (Hingorani et al., 2005)
and KrasLSL-G12D/+;p16/p19/;Cre (Bardeesy et al., 2006) ani-
mals found no additional loss of other major tumor suppressor
genes (TSG) during disease progression, establishing non-over-
lapping mutational spectra in the two model systems. Thus, het-
erozygous mutation of Dpc4 increases the selection pressure to
lose p16, underscoring that WT levels of Dpc4 can be tumor
promoting in this context and that the haploinsufficiency ofs (*p < 0.05, **p < 0.01). (+/+) and (+/) indicate WT and heterozygous deleted
independent animals.
S1.
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Dpc4 in inhibiting primary tumor growth also attenuates meta-
static potential. The spontaneous progression of PDA with
KrasG12D, Trp53R172H, Dpc4+/, and loss of p16 encompasses
all four cardinal mutations seen in human PDA (Iacobuzio-Dona-
hue et al., 2000, 2012).
Heterozygous Loss ofDpc4 Inhibits Metastatic Behavior
Induced by KrasG12D and Trp53R172H
Functional assays were performed to explore the relative met-
astatic deficiency of KPDC pancreas cancers. First, we found
that the epithelial-to-mesenchymal transition (EMT), a program
of morphological and molecular changes implicated in the met-
astatic phenotype, was qualitatively intact in KPDC PDA cells.
KPDC cells developed actin stress fibers in response to TGF-
b (Figures 2A and S2A) and downregulated surface expression
of E-cadherin (Figures 2B and S2B). However, they were less
likely to separate from each other in response to TGF-b than
KPC cells, and, despite their qualitative ability to undergo
EMT, both the basal migration and invasion of KPDC cells
were significantly impaired (Figures 2C–2E, S2C, and S2D).
Moreover, whereas TGF-b-stimulated KPC cells to migrate,
KPDC cell migration was instead either unaffected or further in-
hibited. KPC cells in monolayer culture also readily formed foci
in response to TGF-b, whereas KPDC cells did not (data not
shown).
The cellular phenotypes could be interconverted by depleting
or overexpressing Dpc4 in KPC or KPDC cells, respectively.
Dpc4 depletion in KPC cells inhibited their migration, and over-
expression of Dpc4 in KPDC cells increased theirs (Figures
S2E–S2G). After injection into the circulation, KPC cells formed
numerous large pleural and parenchymal metastases sufficient
to induce respiratory failure, reflecting the metastatic aggres-
siveness seen in their autochthonous counterpart (Figures 2G
and 2H). KPDC cells formed far fewer and smaller lung metasta-
ses in animals that remained clinically robust at comparable time
points (Figures 2F and 2H). Collectively, these studies reveal that
both the baseline properties and responses to TGF-b are essen-
tially mirror images in the presence of WT versus heterozygous
loss of Dpc4.
Runx3 Drives Metastasis in PDA
The dramatically different behaviors of KPC and KPDC
carcinomas suggested that comparative expression profiling
might provide mechanistic insights. Expression analyses using
customized TGF-b-signaling-specific quantitative PCR (qPCR)
arrays identified 15 genes that were upregulated at least 2-fold
in KPC versus KPDC cells and that might therefore represent
metastasis-promoting genes (Table S2). Dpc4 expression was
approximately 2-fold higher in KPC than KPDC cells, confirming
the fidelity of the array results. Completely distinguishing itself
was Runx3, which was upregulated 36-fold in KPC cells (Table
S2). Runx3 belongs to a family of runt-related transcription
factors involved in development and differentiation of which
Runx1 and Runx2 are the best characterized (Blyth et al.,
2005). The specificity of Runx3 upregulation was underscored
by the lack of significant changes in the other family members
(1.2-fold increase for Runx1 and 1.5-fold for Runx2; data not
shown). RUNX1 and RUNX2 have been identified as TSG in1348 Cell 161, 1345–1360, June 4, 2015 ª2015 Elsevier Inc.hematopoietic malignancies. Its alternate designation as acute
myelogenous leukemia 2 (AML2) notwithstanding, what little is
known about the role of RUNX3 in malignancy comes primarily
from studies of solid tumors, where it has been implicated on
both sides of the cancer divide (i.e., as a TSG in some reports
and an oncogene in others). Indeed, its specific role in tumori-
genesis remains the subject of considerable controversy (for
examples, see Ito et al., 2009; Levanon et al., 2001, 2011; Li
et al., 2002; see below).
Runx3 gene expression and protein levels correlated with
metastatic potential (Figures 3A and 3B). In both KPC and
KPDC carcinoma cells, Runx3 was appropriately localized to
the nuclear compartment (Figure S3A), albeit at very different
levels. Specific immunohistochemistry (IHC) for Runx3 revealed
no discernible expression in normal pancreatic ducts, islets, or
acini; scattered lymphocytes, common sites of elevated Runx3
and useful internal controls (Yarmus et al., 2006), showed strong
nuclear expression (Figure 3C). As expected, KPC tumors had
moderate-to-strong nuclear Runx3 expression (Figures 3D and
3E), whereas KPDC tumors typically showed very weak expres-
sion (Figures 3F and 3G). Preinvasive lesions adjacent to invasive
KPC carcinomas also lacked Runx3 expression (Figure 3H). KPC
metastases exhibited strong nuclear Runx3 expression (Fig-
ure 3I) and, in KPDC mice that did bear metastases, both these
and the primary tumors often expressed high levels of Runx3
(Figures 3J–3L). The upregulation of Runx3 as KPC PanIN
become invasive and metastatic coincides with the apparent
requirement for LOH of p53 and subsequent accumulation of
the point mutant protein (Hingorani et al., 2005). These observa-
tions implicate WT p53—reported to complex with RUNX3
(Yamada et al., 2010)—in suppressing Runx3 or point mutant
p53 in stabilizing Runx3.
Runx3 Promotes Metastatic Seeding and Colonization
by Remodeling the Extracellular Matrix
To further investigate its effects on metastatic potential, we var-
ied Runx3 expression in independent KPDC and KPC carcinoma
cell lines (Figures S3B and S3C). Runx3 overexpression greatly
increased the basal migration of KPDC cells, and silencing
Runx3 inhibited KPC cell migration (Figures 3M, S3D, and
S3E). TGF-b stimulated migration only in the context of high
Runx3 expression. Anchorage-independent growth in soft agar
was similarly influenced by changes in Runx3 expression (data
not shown). KPDC$Runx3 cells also readily formed lung metas-
tases in immunocompromisedmice (Figures 3N and 3O), an abil-
ity virtually absent in control-transfected KPDC cells and once
again more like baseline KPC cells. A trend toward reduced
lung metastasis after Runx3 knockdown in KPC cells was also
observed but did not reach statistical significance, perhaps
reflecting incomplete Runx3 silencing (Figures 3P and 3Q).
KPDC cells were unable to efficiently seed metastases even
after direct inoculation into the bloodstream. To successfully
colonize a distant site, disseminated cells must not only intrava-
sate but also survive in the circulation, extravasate in a target
organ, and fashion a niche that supports metastatic growth.
We therefore performed focused array profiling for extracellular
matrix (ECM) genes comparing the highly metastatic KPC and
non-metastatic KPDC PDA cells. A survey of the top differentially
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Figure 2. Dpc4 Status Affects Morphologic and Cellular Behaviors Associated with Metastasis
(A and B) Immunofluorescence of actin stress fibers (A) and surface E-cadherin (B) in representative KPC and KPDC PDA cells with or without TGF-b. Nuclei are
counterstained with DAPI (blue). Scale bars, 50 mm.
(C) Cell migration of representative KPC and KPDC primary PDA cells from three independent experiments (mean ± SEM; *p < 0.0001).
(D and E) Representative images (D) and quantification (E) of KPDC and KPC cells after invasion through Matrigel (n = 6 wells per cell line, *p < 0.005).
(F–H) Representative images (F and G) and quantification (H) of pulmonary metastases after intravenous inoculation. Two different levels from three injected
animals each were assessed (mean ± SEM; *p < 0.05). See also Figure S2.
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Figure 3. Runx3 Promotes Metastasis in Murine PDA
(A) Runx3 qRT-PCR in KC preinvasive (Pre) and KPDC and KPC invasive PDA cells (n = 4-5 each; mean ± SEM; *p = 0.05).
(B) Runx3 immunoblots in representative KPDC and KPC PDA cells. Actin, loading control.
(C) Runx3 expression in normal pancreas. Arrows, lymphocytes; arrowheads, duct; ac, acini; is, islet.
(D) Runx3 expression in undifferentiated region of invasive KPC PDA (arrows). Arrowhead, PanIN-1A.
(E) Runx3 expression in sarcomatoid region of invasive KPC PDA (arrows).
(F and G) Absence of Runx3 in carcinoma cells of two different KPDC PDA (arrowheads).
(H) PanIN in KPC animals lack Runx3 expression (arrowheads).
(I) Runx3 expression (arrows) in KPC liver metastases (outline) from primary PDA in (E); adjacent hepatocytes (h) lack Runx3 (arrowheads).
(J) Runx3 expression (arrows) in region of primary PDA from KPDC animal that developed metastases.
(K) Runx3 expression (arrows) in KPDC liver metastasis from primary PDA in (J) and lack of Runx3 (arrowheads) in adjacent hepatocytes (h). n, area of necrosis.
(legend continued on next page)
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expressed genes revealed several that have been previously
implicated in critical ECM functions, promoting local invasive-
ness and remodeling of the metastatic niche (Psaila and Lyden,
2009) (Table S3). These include Mmps, Timps, Versican, Spp1,
and Sparc (Lunardi et al., 2014).
Osteopontin (SPP1) is upregulated in human PDA and
portends poor prognosis (Poruk et al., 2013). Spp1 protein
(Figure 4A) and transcript levels (Table S3) are also significantly
upregulated in KPC versus KPDC PDA cells. We identified two
consensus RUNX3-binding sites and two SMAD-binding ele-
ments in both the human SPP1 and murine Spp1 promoter
regions and found that the promoter responds toRUNX3 overex-
pression (Figure S4A). Overexpression or silencing of Runx3
in KPDC or KPC cells, respectively, caused corresponding
changes in Spp1 expression (Figures 4B, 4C, S4B, and S4C).
As Spp1 is secreted, we therefore tested whether exogenously
added Spp1 influenced migration. KPDC cell migration
increased significantly in the presence of Spp1, an effect
reversed by a neutralizing Spp1 antibody, which also signifi-
cantly reduced basal KPC cell migration (Figure 4D). Spp1
promotes migration through binding to integrins and CD44 re-
ceptors, which are also upregulated in KPC cells (Table S3),
and we found that anti-CD44 antibody decreased Spp1-medi-
ated migration compared to immunoglobulin G (IgG) control-
treated counterparts (Figure 4D). Finally, if Spp1 secretion is
important for distant colonization, then circulating plasma levels
should be high in mice with metastases regardless of genotype.
Circulating Spp1 was indeed elevated in the majority of KPC
mice, and the relatively few KPDC mice, that developed signifi-
cant metastatic disease burdens (Figure 4E).
Some genes in the ECM profile, including the top-ranked one,
Col6a1, were less familiar (Table S3). COL6A1 binds fibrillar type
I collagen (Bonaldo et al., 1990), itself complicit in PDA aggres-
siveness and dissemination (e.g., Armstrong et al., 2004).
COL6A1 is elevated in the circulating proteome of PDA patients
(Yu et al., 2009), and we found two RUNX3 consensus-binding
sites in the COL6A1/Col6a1 promoter region (data not shown).
Little is known, however, about the specific function(s) of this
gene in cancer and, in particular, in PDA. We first confirmed
that Col6a1 is differentially expressed in KPC and KPDC cells
(Figures 4F and S4D). Overexpression of Runx3 in KPDC cells
increased Col6a1 transcript and protein levels (Figures 4G and
S4D), whereas Runx3 silencing in KPC cells reduced them (Fig-
ures 4H and S4E). We next tested whether Col6a1 could act as
an autocrine enabler of dissemination. KPC cells secrete higher
levels of Col6a1 than KPDC cells (Figure 4I), and overexpressing
Col6a1 in KPDC cells increased migration and silencing Col6a1
in KPC cells inhibited it (Figures 4J and S4F–S4I). Thus, in addi-
tion to providing a potentially critical component of the three-(L) Runx3 expression in KPDC and KPC primary tumors. Each point represents m
(M) Cell migration +/– TGF-b in representative KPDC cells with (Flag-Runx3) or w
(Scr) Runx3 depletion. Data represent three independent experiments (mean ± S
(N and O) Representative lung sections (N) and quantification (O) of pulmonary m
Runx3) KPDC#1 cells. Two different histological levels from a total of three injec
(P and Q) Representative lung sections (P) and quantification (Q) of pulmonarymet
cells. Two different histological levels from a total of three injected animals each
Scale bars, 50 mm. See also Figure S3.dimensional architecture of a developing tumor, Col6a1 also
appears to directly stimulate cell motility. Finally, overexpression
of Col6a1 in KPDC or knockdown in KPC cells reversed their
respective abilities to seed lung metastases after intravenous
injection (Figures 4K and 4L). Overall, these results suggest
that Runx3 serves to both expel the seed and prepare the soil
by directly stimulating cell migration and dissemination, and by
inducing the expression of a repertoire of proteins that can reen-
gineer the extracellular matrix to enhance distant colonization.
Heterozygous Deletion of Dpc4 Increases Proliferation
in the Context of Oncogenic KrasG12D and Trp53R172H
The increased primary tumor size at the expense of metastatic
disease seen in KPDC compared with KPC PDA could be
explained by increased proliferation, decreased apoptosis, or
both. Ki-67 expression was significantly increased in KPDC
versus KPC autochthonous tumors and apoptosis was similarly
negligible in both contexts (Figures 5A–5E). In culture, KPDC
PDA cells were more proliferative than KPC cells (Figure 5F)
and had similarly low apoptotic rates (data not shown). KPDC
cells were also somewhat less sensitive to growth arrest by
TGF-b (Figure 5F). Substantiating its sometime designation as
a TSG, silencing Runx3 in KPC cells unleashed proliferation
and overexpression of Runx3 in KPDC cells inhibited it (Figures
5G and 5H). We identified multiple consensus Runx3 binding
sites in the p21Cip1/Waf1 (Cdnk1a) promoter region and confirmed
that Runx3 stimulated its expression (Figure 5I), as previously
demonstrated in gastric epithelial cells (Chi et al., 2005).
Rare Metastasis of KPDC PDA Requires LOH of Dpc4
The above findings prompted an analysis of Dpc4 status in
paired primary tumors and metastases in the few KPDC animals
that did develop disseminated disease. The primary tumors re-
vealed focal areas of Dpc4 loss, suggesting a potential source
for the disseminated cells (Figures 6A and 6B). In addition, a
strong inverse correlation was observed between Dpc4 and
Runx3 expression in primary tumors and metastases (Figures
6C and 6D): complete loss of Dpc4was associated with elevated
levels of Runx3, whereas retained Dpc4 corresponded with
low-to-undetectable Runx3 (Figure S5A). These observations
suggested that completing the loss of Dpc4 in PDA cells that
had undergone a first (heterozygous) ‘‘hit’’ may confer metastatic
potential on cells that previously lacked it, perhaps by increasing
Runx3.
To directly investigate the effects of homozygous loss of Dpc4
on autochthonous PDA, we generated and characterized
KrasLSL-G12D/+;Trp53LSL-R172H/+;Dpc4flox/flox;p48Cre/+ (KPDDC)
quintuple mutant mice. KPDDC mice had a median survival of
125 days, significantly shorter than both KPDC and KPC cohortsean of 3 hours post fertilization (hpf) from an independent animal (*p < 0.05).
ithout (Flag) Runx3 overexpression, and in KPC cells with (shRunx3) or without
EM; *p < 0.01).
etastases in mice injected with control (Flag) or Runx3-overexpressing (Flag-
ted animals for each condition were assessed (mean ± SEM; *p < 0.005).
astases in mice injected with control (Scr) or Runx3-depleted (shRunx3)KPC#1
were assessed (mean ± SEM; p = 0.21).
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Figure 4. Runx3 Stimulates Expression of Pro-metastatic ECM Components
(A) Immunoblots for Spp1 in KPDC and KPC primary PDA cells.
(B) Immunoblots for Spp1 in control () and Runx3-overexpressing (+) KPDC cells.
(C) Immunoblots for Spp1 in control () and Runx3-knockdown (+) KPC cells.
(D) KPDC and KPC primary carcinoma cell migration under the indicated conditions, representative of three independent experiments (mean ± SEM; *p < 0.001).
(E)CirculatingSpp1 inKPCandKPDCanimalswith (+)orwithout ()metastaticdisease.Points represents themeanofduplicatemeasurements frommice (*p<0.005).
(F) Immunoblots for Col6a1 in independent KPDC and KPC primary PDA cell preparations. (Loading control was the same as in A.)
(G) Immunoblots for Col6a1 in control (Flag) and Runx3-overexpressing (Flag-Runx3) KPDC cells. (Loading control was the same as in B.)
(H) Immunoblots for Col6a1 in control (, Scr) and Runx3-depleted (+, shRunx3) KPC cells. (Loading control was the same as in C.)
(I) Col6a1 immunoblots of conditioned media from KPC and KPDC cell lines. Tenascin C, loading control.
(J) KPDC and KPC primary carcinoma cell migration +/– Col6a1 overexpression (Col6a1) or depletion (shCol6a1), respectively. Mean ± SEM of three independent
experiments (*p < 0.0001).
(K) Representative lung sections from mice injected intravenously with either depleted or overexpressed Col6a1 in KPC and KPDC cells, respectively (n = 2 cell
lines and three animals for each condition).
(L) Quantification of metastatic pulmonary tumor burden from assays in (K). Two different histological levels from a total of three injected animals were assessed
(mean ± SEM; *p < 0.05).
See also Figure S4.
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Figure 5. Runx3 Inhibits Proliferation in Invasive PDA Cells
(A and B) Ki-67 expression in autochthonous (A) KPDC and (B) KPC PDA.
(C and D) Cleaved caspase 3 in autochthonous (C) KPDC and (D) KPC PDA.
(E) Proliferation in autochthonous KPDC and KPC tumors (mean ± SEM, *p < 0.05).
(F) Proliferation of purified PDA cells +/– TGF-b in vitro (n = 3, mean ± SEM; *p < 0.001).
(G) Proliferation of control (Scr) and Runx3-knockdown (shRunx3) purified primary KPC cells in vitro (n = 3, mean ± SEM; *p < 0.001).
(H) Proliferation of control (Flag) and Runx3-overexpressing (Fl-Runx3) purified KPDC cells in vitro (n = 3, mean ± SEM; *p < 0.001).
(I) Immunoblots for p21 in control and Runx3-overexpressing KPDC cells and control and Runx3-depleted KPC cells. Fold changes were quantified by densi-
tometry and normalized to actin.
Scale bars, 50 mm.(data not shown). Large, multinodular pancreas tumors were
found to develop from PanIN precursors (Figures S5B and
S5C) and were histologically indistinguishable from KPDC or
KPC PDA (Figures S5D and S5E). KPDDC primary tumors grew
much faster than KPDC and KPC PDA, as may be expected
from complete loss of canonical TGF-b signaling (Figure S5F).
In addition, KPDDC mice exhibited metastases to the liver and
lungs at similar frequencies (73%) to KPC mice, a capability re-
flected in the elevated levels of Runx3 in KPDDC primary tumors
(Figure S5G) and purified cells (Figure S5H). This combination of
unfettered proliferation and potent dissemination explains the
rapid demise of KPDDC mice and is consistent with the subset
of especially aggressive human PDA with a similar mutational
profile (Yachida et al., 2012). In keeping with the role of Runx3
in modulating ECM gene expression to promote metastasis,
Spp1 and Col6a1 were also elevated in KPDDC compared to
KPDC cells (Figure S5H). Despite their considerable metastaticcompetency in vivo, KPDDC cells were nevertheless notably
resistant to induction of EMT by TGF-b in vitro (Figures 6E, S5I,
and S5J). Collectively, these findings suggest a biphasic depen-
dency of metastatic potential on Dpc4—mirrored in Runx3
levels—with heterozygous mutation retarding, and subsequent
LOH rescuing, the ability to disseminate (Figure 6F).
Multiple Inputs Regulate Runx3 Levels
In considering how Runx3 levels might be regulated, three
pieces of information provided useful starting points: (1) the dra-
matic fall and rise in Runx3 levels with stepwise loss of Dpc4; (2)
the increase in Runx3 levels coordinately with LOH of p53 inKPC
PDA progression; and (3) the presence of multiple consensus
binding sites for the Runx3 transcription factor in its own pro-
moter. Although the detailed mechanisms behind the complex
regulation of Runx3 levels remain to be elucidated, a working
model can nevertheless be elaborated from our findings andCell 161, 1345–1360, June 4, 2015 ª2015 Elsevier Inc. 1353
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Figure 6. Dpc4 and Runx3 Coordinately Regulate Metastatic Behavior in PDA
(A) Spontaneous focal loss of Dpc4 (left) in representative autochthonous KPDC PDA correlates with acquired Runx3 expression (right). Yellow boxes and
arrowheads indicate areas of focal Dpc4 loss and acquired Runx3 expression in tumor epithelia; red boxes and arrows indicate regions of Dpc4 retention and
undetectable Runx3.
(B) Liver metastases (asterisks and dotted outlines) from KPDC mice reveal spontaneous loss of Dpc4 and corresponding increases in Runx3 expression
(arrowheads). Note that hepatocytes (h) retain Dpc4 and do not express Runx3.
(C and D) Quantification of Dpc4 and Runx3 IHC in (C) glandular structures in primary KPDC tumors and (D) liver metastases from KPDC mice. Runx3-low
structures/metastases are represented by open bars and Runx3-high by black bars. Fisher’s exact test revealed a significant correlation between Dpc4 loss and
Runx3 expression (**p < 0.0005, *p < 0.005).
(E) Immunofluorescence of actin stress fibers (upper panels) and surface E-cadherin (lower panels) in KPDDC cells +/– TGF-b. Nuclei are counterstained with
DAPI (blue).
(F) Metastatic potential (F) plotted as fraction of mice exhibiting metastases (red, ± 95% confidence interval) and relative Runx3 protein levels (black outlined
bars; mean ± SEM) as a function of Dpc4 status (green).
(G) Model for the regulation and role of Runx3 in proliferation and metastasis of PDA. Runx3 levels are influenced by Dpc4 status in a biphasic manner and
increase only after LOH of Trp53 in the context of point mutant Trp53. Runx3 expression, in turn, stimulates synthesis and secretion of proteins that promote
migration and metastatic niche preparation, while simultaneously inhibiting proliferation.
Scale bars, 50 mm. See also Figure S5.
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corroborated experimentally (Figure 6G). First, we hypothesized
that WT p53 promotes Runx3 protein degradation and that point
mutant p53 rescues this effect. This predicts therefore that pro-
tein stability would be highest in invasive KPC cells and that
Runx3 stability should otherwise be comparable in KPDC and
KPDDC cells (as both undergo LOH of p53), unless Dpc4 status
additionally contributes. We incubated cells in cycloheximide to
arrest protein synthesis and followed the kinetics of Runx3
degradation: protein levels were indeedmost stable inKPC cells,
and the already low Runx3 levels in KPDC cells dropped even
further (Figures S5K and S5L). These findings suggested that ho-
mozygous levels of Dpc4 promoted Runx3 synthesis (which
would most readily be accomplished at the transcriptional level)
and that heterozygous levels were sufficient to promote Runx3
protein degradation. We predicted therefore that restoring
Dpc4 expression in KPDC cells would increase Runx3 transcript
levels and that partial knockdown in KPC would decrease them,
both of which were observed (Figures S5M and S5N). That the
basal protein levels are both elevated andmore stable in KPDDC
than KPDC cells is also consistent with this interpretation, but
suggests the presence of at least one more input into Runx3
transcription, perhaps Runx3 itself. In this scenario, once the
concentration of the Runx3 transcription factor achieves a crit-
ical threshold, it further promotes its own transcription. The
Runx3 promoter contains three consensus Runx3 binding sites,
prompting us to test this hypothesis directly in reporter assays
with increasing amounts of exogenous Runx3 (Figure S5O).
As shown, once Runx3 rises above a certain level, it rapidly in-
creases its own transcription.
RUNX3 Drives Metastasis in Human PDA
To determine whether RUNX3 served similar roles in human
pancreas cancer, we first assessed protein levels in a panel of
well-characterized human PDA cell lines (Figure 7A). There are
wide differences across these extensively passaged cell lines
in the mutational status of the principal TSG, and even among
multiple reports of a single line (Deer et al., 2010). Moreover, as
disease behavior may also reflect the chronologic sequence in
whichmutations arise (see Izeradjene et al., 2007) andwe cannot
know that history, we asked whether RUNX3 levels alone could
be used to infer metastatic capability. We chose two of the high-
est (CFPAC-1 and Panc-1) and one of the lowest (MiaPaCa-2)
RUNX3-expressing lines for further study (Figure 7A). We note
that, although MiaPaCa-2 cells are WT for DPC4, they contain
markedly decreased—but not completely absent—levels of
TGF-bR2 (data not shown), suggesting an alternative way to
attenuate DPC4-mediated signaling and potentially produce
the same functional outcome.
Basal levels of RUNX3 predicted migration, as MiaPaCa-2
cells migrated less well than either CFPAC-1 or Panc-1 cells (Fig-
ures 7B and 7C). The respective responses of these cell lines to
TGF-b also followed the pattern seen with murine PDA cells:
TGF-b modestly inhibited MiaPaCa-2 cell migration, as it did
with KPDC cells, whereas it promoted (or left unaffected) the
high basal migration of CFPAC-1 and Panc-1 cells, similar to
KPC cells. Overexpression of RUNX3 in MiaPaCa-2 cells (Fig-
ure S6A) greatly increased migration (Figures 7B and S6B).
Conversely, depletion of RUNX3 in both Panc-1 cells andCFPAC-1 cells inhibited migration (Figures 7C, S6C, and S6D).
Anchorage-independent growth of MiaPaCa-2 and CFPAC-1
cells was similarly influenced by RUNX3 overexpression and
knockdown, respectively (Figures S6E and S6F). MiaPaCa-2
cells overexpressing RUNX3 developed a significantly greater
metastatic burden after intravenous inoculation into NOD.SCID
mice than vector-control cells (Figures 7D and 7E). Conversely,
targeted depletion of RUNX3 in Panc-1 cells diminished their
overall metastatic potential. Although both control and RUNX3-
knockdown Panc-1 cells produced a comparable metastatic
burden in the lungs (Figure S6G), the ability to seed and support
secondary livermetastaseswas significantly impaired byRUNX3
depletion as reflected in the distinct gross pathology (Figure 7F)
and liver weights between the two groups: 4.3 ± 0.6 g (n = 4)
versus 0.53 ± 0.06 g (n = 3; p < 0.005), respectively. SPP1 and
COL6A1 expression levels were also influenced as expected
by modulating RUNX3 expression in these respective human
cell lines, and COL6A1 overexpression stimulated migration
(Figures S6H–S6K). Thus, the RUNX3-dependent metastatic
drive and responses to TGF-b observed in human PDA cells
paralleled the behaviors of their murine counterparts.
RUNX3 Predicts Survival and Disease Behavior in
Human PDA
Cohorts of PDA patients with evaluable tissue and long-term
survival data are rare. Using the available resources, we investi-
gated whether RUNX3 levels in primary tumors influenced
disease behavior and survival after surgery and could even pre-
dict response to various forms of therapy. Given the predilection
for distant relapse after surgery, we hypothesized that high
RUNX3 levels in primary PDA epithelial cells might portend
poor prognosis. In a cohort of PDA patients who underwent
definitive resection (n = 88), RUNX3 levels did indeed correlate
with survival (Figures 7G, S6L, and S6M). Since no information
was available in this data set on site of relapse, we interrogated
a separate annotated cohort assembled by The International
Cancer Genome Consortium (ICGC) that included whole-tissue
transcriptome analyses and data on relapse pattern and survival
after surgery. In this case, RUNX3 transcript levels did not corre-
late with either survival or relapse site, an unsurprising result
given that PDA are dominated by inflammatory cells with high
baseline RUNX3 levels, and whole-tissue preparations from bi-
opsies would inevitably include transcripts from all cell popula-
tions. We instead assessed the downstream targets of epithelial
RUNX3 expression and found elevated tissue levels of SPP1 and
COL6A1 in patients who developed distant as opposed to local
disease recurrence after surgery (Figure 7H).
As a final measure of potentially actionable information con-
tained in RUNX3 levels, we investigated whether they could
help inform the choice and sequencing of different treatment
modalities in the post-operative and, by extension, pre-operative
settings. We reasoned that patients with lower levels of RUNX3
might respond better to radiotherapy, given the higher risk of
local relapse, whereas patients with high RUNX3 might fare
better with systemic therapy. As predicted, the use of local radi-
ation favored patients with low RUNX3 (Figure 7I). Conversely,
patients with high RUNX3 benefitted most from systemic treat-
ment, whereas those with low RUNX3 did not (and may evenCell 161, 1345–1360, June 4, 2015 ª2015 Elsevier Inc. 1355
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Figure 7. RUNX3 Promotes Metastasis in Human PDA
(A) Immunoblots for RUNX3 in human PDA lines.
(B) Migration of control (Flag) and RUNX3-overexpressing (Flag-RUNX3) MiaPaCa-2 cells +/– TGF-b (n = 3, mean ± SEM, *p < 0.05, **p < 0.01).
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metastases.
(E) Quantifiedmetastatic pulmonary tumor burden from assays in (D). Two histological levels from three injected animals were assessed (mean ± SEM; *p < 0.05).
(F) Livers in vivo (left) and ex vivo (right) from NOD.SCID animals injected with control (Scr) or RUNX3-knockdown (shRUNX3) Panc-1 cells. Arrows, metastases.
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(legend continued on next page)
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have been harmed given that low RUNX3 should otherwise
portend a better prognosis). These analyses support the idea
that RUNX3 levels in the primary tumor may help inform the
management of pancreas cancer patients.
DISCUSSION
We systematically varied Dpc4/Smad4 gene dosage in
KrasG12D/+;Trp53R172H/+;p48Cre/+ (KPC) PDA recapitulating the
spectrum of disease presentations encountered in patients
and identified the Runx3/RUNX3 transcription factor as the
convergence point for several inputs that ultimately govern
the balance between cell division and dissemination. RUNX3
slows the proliferation of PDA cells while endowing them
with the ability to both migrate to and participate in the con-
struction of the metastatic niche by secreting critical stromal
matrix constituents. These findings suggest additional thera-
peutic targets in pancreas cancer and have the potential to
inform clinical decision-making at key junctures in disease
management.
Balancing Proliferation and Dissemination in PDA
The cellular demands of proliferation and dissemination appear
to compete in pancreas cancers, at least until Dpc4 signaling is
completely lost. Our data suggest that partial attenuation of
TGF-b signaling shifts the burden of disease toward primary
tumor growth by lowering barriers to proliferation at the
expense of sacrificing mediators of metastasis. Governing
this switch is the transcription factor Runx3, which integrates
inputs from Dpc4 and Trp53 (Figure 6G) to generate three
broad sets of biological behavior. These shifts in pathobiology
with mutational state also help explain patterns of spread
observed in patients. At one extreme are patients with locally
invasive and destructive tumors and minimal discernible
dissemination; at the other are patients with a more restricted
primary tumor but widespread metastases. Complete loss of
Dpc4 in the context of point mutant Trp53 reveals a third state:
uninhibited primary tumor growth together with high metastatic
potential.
It may seem paradoxical that diminution of Dpc4 signaling can
impede dissemination, given that loss of expression frequently,
though not always (Iacobuzio-Donahue et al., 2009), occurs in
PDA metastases. However, the precise levels of signaling
appear to be critically important. Approximately half of conven-
tional PDA lose expression of DPC4/SMAD4 and this is thought
to represent a late event (Wilentz et al., 2000). As these data are
derived from IHC observations, they are generally bimodal (i.e.,
all or none) and cannot reliably report heterozygous loss of
DPC4. In autopsy series of PDA patients, a range of metastatic
disease burdens has been observed, with death not infrequently
attributable to local destruction as opposed to disseminated dis-
ease (Iacobuzio-Donahue et al., 2009). Two distinct patterns of
metastatic spread emerge: widely metastatic disease character-(J) RUNX3 and DPC4 levels coordinately help inform clinical decision making fo
proscriptive advice. Future prospectively collected information, perhaps augment
this working framework. 1An alternative would be a short course of radiotherapy
See also Figure S6.istic of the majority of cases and an oligometastatic state in a
minority. In light of our findings, themost aggressive disease pre-
sentation plausibly involves heterozygous mutation of DPC4
relatively early in disease progression, promoting aggressive
local growth and invasion; subsequent loss of DPC4 expression
from the remaining allele in a subclone would then give rise to a
highly metastatic subpopulation. Indeed, in the few KPDC
animals that showed metastatic disease, the tumor cells in
those metastases had frequently lost Dpc4 expression. In this
setting, survival would be threatened by the sequelae of both
local and disseminated disease burdens in a highly lethal
combination.
Resolving Conflicting Roles of RUNX3 in Tumor
Progression
RUNX3 has previously been proposed as both promoting and
suppressing cancer progression, and sometimes ascribed con-
tradictory roles in the same cancer. Although several studies
point toward a tumor suppressive role for RUNX3 (e.g., Bae
and Choi, 2004; Lee et al., 2013), a small number of reports indi-
cate that its oncogenic activity might extend beyond murine
lymphomas to include basal cell, skin, head and neck, and
ovarian cancers (Chuang and Ito, 2010). In gastric carcinoma,
RUNX3 has been identified as both a TSG (e.g., Li et al., 2002)
and an oncogene (e.g., Levanon et al., 2011). The controversy
notwithstanding, these studies may in fact reflect a multifaceted
role for RUNX3 signaling, consistent with the dual and context-
dependent role of TGF-b signaling as a whole. We propose
thatRUNX3 indeed functions as both tumor suppressor and pro-
moter, depending not only on the genetic and cellular contexts
but also on the specific behavior in question, namely, primary
tumor growth or metastatic spread.
EMT and Disease Dissemination: An Imperfect
Relationship
Both highly metastatic (KPC) and poorly metastatic (KPDC) PDA
cells manifested the classic phenotypic and molecular features
of EMT in response to TGF-b. Epithelial cells from highly meta-
static KPDDC tumors, on the other hand, were resistant to
EMT and remained in close contact with each other. Thus,
attempting to extrapolate the potential to metastasize in vivo
from the ability to morph in vitro seems tenuous at best. Indeed,
despite its intuitive appeal as the malignant mimic of the cellular
plasticity required during embryogenesis, positing the EMT as an
essential feature of the metastatic program remains controver-
sial (Tarin et al., 2005). The considerable in vitro data in support
of the concept are counterbalanced by a lack of in vivo evidence
in autochthonous human cancers. Our data suggest that if EMT
does occur, it is not the only means by which metastases can
develop, at least not in pancreas cancer. RUNX3 may promote
distinct, perhaps overlapping, metastatic programs involving
the dissemination of both single cells and groups or clusters of
cells, a possibility first considered over four decades ago (Fidler,r resectable PDA. These considerations are exploratory and not intended as
edwith retrospective analyses, will be essential to substantiate, revise, or reject
followed by chemotherapy.
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1973) and revisited more recently (Friedl and Alexander, 2011).
As a principal cause of cancer mortality, understanding the basis
for and learning how to inhibit metastasis are of more than aca-
demic interest. Current efforts to target specific features of EMT
as a strategy for disrupting dissemination may be incomplete,
and the model systems developed and described here revealing
distinct metastatic programs may prove fruitful in future
investigations.
Local Growth versus Disseminated Disease:
Therapeutic Implications
The unusual ability of PDA to spread has spurred efforts to
advance systemic neoadjuvant therapies and address at the
outset the almost inevitable and frequently rapid appearance
of metastases. This strategy is not without risks: beyond the po-
tential toxicities looms the possibility that a previously contained
tumor will breach the immediate confines of resectability.
Indeed, a minority of early-stage (I/II) or locally advanced (stage
III) tumors are destined to remain local; these patients can often
be managed for many months with no overt evidence of dissem-
ination. In such patients, treating with chemotherapy first and
delaying surgery may forfeit the rare window to operate. In a
large meta-analysis of over 4,000 early-stage pancreas cancer
patients who received some form of neoadjuvant therapy, fully
30% became inoperable during the course of treatment (Gillen
et al., 2010). The ideal types, timing, duration, and sequence of
adjuvant chemotherapy and radiotherapy are also unclear, with
the role of radiation being especially contentious (Katz et al.,
2010). Conflicting results in the setting of complex trial designs
have confounded meaningful comparisons and precluded
consensus on how best to incorporate distinct modalities into
PDA management.
Taking the specific case of early-stage disease as an example,
distinguishing those patients to treat with neoadjuvant therapy
from those to resect immediately remains especially challenging.
The studies presented here suggest thatRUNX3may help inform
such decisions, particularly when interpreted in the context of
DPC4 status (Figure 7J). High levels of RUNX3 increase the
migratory and metastatic potential of both murine and human
PDA cells, which, in the context of intact DPC4, defines the
most likely cause of death. These patients would likely benefit
most from initial systemic therapy followed by resection given
the comparatively lower risk for local growth. Patients with
resectable disease and low RUNX3 levels benefit less from
systemic treatment up front and should instead be resected (or
treated with a short course of radiation prior to resection, if
needed). Patients with high RUNX3 and complete loss of DPC4
pose the greatest challenge: if neoadjuvant therapy is attempted
at all, it maymake sense to invert the normal sequence and give a
short course of chemoradiation to achieve some local control
prior to systemic cytotoxics; however, the primary tumor must
be followed closely so as not to lose the opportunity for a defin-
itive resection. Alternatively, combining systemic therapy with
cell-cycle inhibitors may allow treatment of occult disseminated
disease while minimizing the risks of local tumor growth. These
admittedly speculative hypotheses nevertheless suggest a
framework for future studies that will ultimately provide the
measure of their merit.1358 Cell 161, 1345–1360, June 4, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
Additional experimental details can be found in Supplemental Experimental
Procedures.
Mouse Strains
All animal studies were approved by the Institutional Animal Care and Use
Committee of the Fred Hutchinson Cancer Research Center (FHCRC).
ConditionalTrp53LSL-R172H/+,Dpc4flox/+,KrasLSL-G12D/+, andp48Cre/+micestrains
described earlier (Hingorani et al., 2003, 2005; Izeradjene et al., 2007) were
interbred to obtain KrasLSL-G12D/+;Trp53LSL-R172H/+;Dpc4+/+;p48Cre/+ (KPC),
KrasLSL-G12D/+;Trp53LSL-R172H/+;Dpc4flox/+;p48Cre/+ (KPDC), KrasLSL-G12D/+;
Trp53LSL-R172H/+;Dpc4flox/flox;p48Cre/+ (KPDDC), and various littermate control
animals on a mixed background. Nude mice (Athymic NCr-nu/nu, NCI)
and NOD.SCID/NCr mice (CCEH Specialized Mouse Services, FHCRC) were
used in pulmonary metastasis assays.
Histology and Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin,
and 5-mm sections were prepared. Routine H&E and immunohistochemistry
(IHC) were performed as previously described (Hingorani et. al., 2003) and
IHC scoring was done blinded. Biotinylated secondary antibody and the Elite
vectastain kit (Vector Laboratories) were used for signal detection and DAB
was used as a chromogen substrate. Primary antibodies: amylase (1:800,
Sigma); CK-19 (DakoCytomation); cleaved caspase 3 (1:100, Biocare); Dpc4
(1:300, Abcam); insulin (1:200, Dako); Ki-67 (1:25, Dako); and Runx3 (1:200
for murine and 1:100 for human IHC, Cell Signaling Technology).
Assessment of Primary and Metastatic Disease Burden
Complete necropsies were performed on all study animals. Gross pathology
and histopathology of all internal organs were analyzed for macroscopic
and microscopic disease, respectively. Primary (1) histology was defined
as representing R50% assessed tissue; secondary (2) histology involved
>25% but <50%.
Statistical Analyses
Unless otherwise indicated, the significance of data was determined by the
Student’s t test (two-tailed) for all in vitro studies. A value of p < 0.05 was
deemed significant. Fisher’s exact t test was performed for comparison of
metastatic disease burdens in KPC versus KPDC cohorts. All statistical ana-
lyses were performed using GraphPad Prism 6.0 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.04.048.
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